

EMMA VIENNA – Program

Thursday, January 26, 2023

EDUCATIONAL DINNER BUFFET

Welcome

Heinz Ludwig and Jesús San Miguel

19.00 Buffet opening

19.30-20.00 Management of patients with solitary plasmacytoma, extramedullary myeloma and plasma cell leukemia

Kwee Yong

Friday, January 27, 2023

8.30-8.40 Opening

Heinz Ludwig and Jesús F. San-Miguel

MYELOMA BIOLOGY AND RISK STRATIFICATION

Moderator: Heinz Ludwig

8.40-9.00 Molecular pathogenesis of MM

Niccolò Bolli

9.00-9.20 The role of the immune environment in evolution and course of myeloma

Charlotte Pawlyn

9.20-9.40 Genetic risk classification of multiple myeloma

Jill Corre

9.40-10.10 Discussion around important questions

- Do genomic patterns predict progression of SMM
- Should MGUS/SMM be classified according genomic patterns

- What can be done to modify the immune environment
- Has the time come for revision of risk factors
- Are epigenetic compounds underused

10.10-10.30 BREAK

NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT

Moderator: Jesús San Miguel

10.30-10.50 MRD based treatment decisions - ready for clinical practice?

Bruno Paiva

10.50-11.10 Standard and novel imaging approaches in multiple myeloma

Elena Zamagni

11.10-11.30 Circulating plasma cells and mass spectrometry for diagnosis, disease evaluation, and prognostication

Noemi Puig

11.30 -12.00 Discussion around important questions

- Requirements of regulatory agencies for approving MRD
- Circulating plasma cells for disease and response assessment
- Optimizing imaging technologies – MRI and PET/CT
- Impact of higher M-protein detection sensitivity (MGUS and MRD)
- MRD assessment and MGUS-like MM

WORKSHOPS

12.00-12.45 Prevention and treatment of bone disease

Evangelos Terpos

12.00-12.45 Management of patients with high-risk disease

Francesca Gay

12.00-12.45 MGRS and management of cast nephropathy induced acute renal failure

Graham Jackson

12.45- 13.45 LUNCH

MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE

Moderator: Heinz Ludwig

13.45-14.05 Risk classification of MGUS and SMM

Heinz Ludwig

14.05-14.25 Is autologous transplantation still the optimal approach in young patients?

Philippe Moreau

14.25-14.45 Expanding options for maintenance treatment

Michele Cavo

14.45-15.15 Discussion around important questions

- Can prediction of early progression in SMM be further improved?
- Upfront ASCT yields longer PFS but similar OS compared to delayed or no ASCT. Does this principle apply to SMM as well?
- What is the optimal number of induction and consolidation cycles?
- MRD guide therapy ready for prime time?
- Maintenance therapy tomorrow?

15.15-15.35 BREAK

MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS

Moderator: Jesús San Miguel

15.35-15.55 Classification of fitness and comorbidities of patients not eligible for ASCT

Alessandra Larocca

15.55-16.15 How do I select treatment for TNE patients? Pros and Cons for continued treatment

Thierry Facon

16.15-16.45 Discussion of important questions

- Treatment of very elderly patients
- Myeloma related versus other comorbidities
- Initiation of therapy at biochemical progression
- Treatment duration
- Impact of individual risk on treatment selection

16.45-17.30 WORKSHOPS (repeated)

KEYNOTE LECTURE

17.30-18.00 Multiple myeloma research and treatment on the move. A look into the future

Jesús San-Miguel

Saturday, January 28, 2023

THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE

Moderator: Heinz Ludwig

8.30-8.50 How I select therapy after relapse to one or two prior treatment lines

Marivi Mateos

8.50-9.10 Treatment strategies in patients after ≥ 3 relapses

Mohammad Mothy

9.10-9.30 Recently approved drugs (Blenrep, Selinexor, Melflufen) and new IMiDs

Enrique Ocio

9.30-10.00 Discussion of important questions

- Limitations of the definition of refractoriness
- Management of early relapse
- Lenalidomide refractory patients
- CD38 retreatment
- Optimizing therapy in high-risk RRMM patients

10.00-10.20 BREAK

HOT TOPICS IN MYELOMA

Moderator: Jesús San Miguel

10.20- 10.40 BiTEs and monoclonal antibodies

Niels van de Donk

10.40 -11.00 CAR-T cells and other cellular therapies

Hermann Einsele

11.00-11.30 Discussion of important questions

- Resistance mechanisms for CD38 antibodies
- Is there an optimal target for BiTEs and CAR-T cells?
- Pros and cons for BiTEs or CAR-T cells
- Impact of CAR-T cell persistence on outcome
- Prevention of toxicities of BiTEs and CAR-T cells

AMYLOIDOSIS AND WADENSTRÖM'S DISEASE

Moderator: Heinz Ludwig

11.30-11.50 New developments in the management of Amyloidosis

Giampaolo Merlini

11.50-12.10 New developments in the management of Waldenström's disease

Melitios A. Dimopoulos

12.10-12.40 Discussion of important questions

- Is cure a realistic goal in amyloidosis?
- Cellular therapies in amyloidosis
- Treatment of patients failing to first-line treatment with PTK inhibitors and CD20+ base therapies
- Should anti-BCMA treatments be explored in Waldenström's disease as 2/3 express BCMA on their tumor clones?

12.40-12.50 Closure of the meeting

Heinz Ludwig and Jesús San Miguel